Physician profile
John R Esters
NPI 1033390265
$2,329.46
in general payments reported to CMS, 2019-2025
11 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.84 · 2020: $85.77 · 2021: $1,328 · 2022: $172 · 2023: $121 · 2024: $280 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,574.85 | 2020-2025 | |
| Allergan, INC. | $272.54 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $179.78 | 2022-2025 | Vyzulta, Miebo |
| Abbvie INC. | $107.41 | 2022-2023 | |
| Oyster Point Pharma, INC. | $51.90 | 2024-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $32.25 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $25.24 | 2024 | Xdemvy |
| Alcon Vision LLC | $24.75 | 2024 | Clareon |
| Aerie Pharmaceuticals, INC. | $24.18 | 2020 | |
| Shire North American Group INC | $19.42 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Esters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.